Main Article Content

Roman Casciano
Jean-Eric Tarride
Marie Claude Breton
Lee Stern
Anatoly Langer


coronary disease, health economics, Canadian healthcare system



To determine a 16-week total healthcare cost and the cost-effectiveness of short-term, lipid- lowering therapy with atorvastatin 80 mg following acute coronary syndrome (ACS) in Canada.



The expected costs per patient on atorvastatin 80 mg per day and placebo were compared using clinical outcome data from the MIRACL study and cost data from the Ontario Case Costing Project and the Ontario Schedule of Benefits. The cost per event avoided was also assessed.  The clinical outcomes measured included: death, cardiac arrest, non-fatal myocardial infarction (MI),

fatal MI, angina pectoris, stroke, congestive heart failure, and surgical or percutaneous coronary

revascularizations.   All direct medical costs from the perspective of the Canadian health care system were taken into account.



The total expected cost per patient was $2,590 in the placebo group and $2,639 in the atorvastatin group.  The incremental cost of atorvastatin treatment ($49.26 per patient) corresponded to a cost

of $1,285 per event avoided.  The cost savings obtained through the reduction in events offset

86% of the cost of atorvastatin treatment.  Budget impact analysis revealed that increased rates of atorvastatin usage following ACS were associated with large numbers of events avoided at a small additional cost when projected to the Canadian population.



In Canada, the clinical benefits of intensive short-term atorvastatin treatment administered within

96 hours after ACS were associated with a favorable cost-effectiveness ratio. The incremental cost of atorvastatin is mostly offset by savings due to the reduction in events in patients treated with atorvastatin.

Abstract 275 | PDF Downloads 172


1. Health Canada, Heart Disease and Stroke in Canada, 1997: Economic Impact of Cardiovascular Disease [data extracted from: Economic Burden of Illness in Canada, 1993].
2. The Changing Face of Heart Disease and Stroke in Canada, 2000.
3. Statistics Canada, Laboratory Centre for Disease Control, 1996.
4. Castelli WP. Epidemiology of coronary heart disease: the Framingham study. Am J Med 1984;76(2A):4-12.
5. Neaton JD, Blackburn H, Jacobs D, Kuller L, Lee DJ, Sherwin R, Shih J, Stamler J, Wentworth D. Serum cholesterol level and mortality findings for men screened in the Multiple Risk Factor Intervention Trial. Arch Intern Med 1992;152(7):1490-500.
6. Davey-Smith G, Shipley MJ, Marmot MG, Rose G. Plasma cholesterol and mortality: The Whitehall Study. JAMA 1992;267:70-6.
7. Chen Z, Peto R, Collins R, MacMahon S, Lu J, Li W. Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations. BMJ 1991;303(6797):276-82.
8. The Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
9. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996;335(14):1001-1009.
10.Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333(20):1301-7.
11.Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM Jr. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998;279(20):1615-22.
12.Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57
13. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998;338(21):1488-97.
14. FRagmin and Fast Revascularization during InStability in Coronary artery disease (FRISC II) Investigators. Invasive compared with non- invasive treatment in unstable coronary artery disease: FRISC II prospective randomized multicenter study. Lancet 1999;354(9180):708-15
15. Antman EM, Cohen M, Bernink PJ, McCabe CH, Horacek T, Papuchis G, Mautner B, Corbalan R, Radley D, Braunwald E. The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. JAMA 2000;284(7):835-42.
16.Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Chaitman BR, Leslie S, Stern T. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001;285(13):1711-8
17.Buller N, Gillen D, Casciano R et al. A pharmacoeconomic evaluation of the myocardial ischaemia reduction with aggressive cholesterol lowering (MIRACL) study in the United Kingdom. Pharmacoeconomics 2003;21Suppl.1:25-32.
18.Olsson N, Casciano R, Stern L, Svangren P. A Pharmacoeconomic Evaluation of Aggressive Cholesterol Lowering in Sweden. International Journal of Cardiology 2003, in press.
19.Ontario Case Costing Project. Management information system database, Ontario. Toronto: Ontario Case Costing Project (OCCP); 1996.
20.Ontario Health Insurance (OHIP) Schedule of Benefits and Fees. Ontario Ministry of Health and Long-term Care; 2000.
21.Statistic Canada. http://www.statcan.ca/english/Pgdb/Economy/Ec onomic/econ09g.htm
22.McGhan W. Pharmacoeconomics and the evaluation of drugs and services. Hosp Formul 1993; 23:365-378.
23.Jolicoeur LM, Jones-Grizzle AJ, Boyer JG. Guidelines for performing a pharmacoeconomic analysis. Am J Hosp Pharm 1992;49:1721-1747.
24. O'Brien BJ, Drummond MF, Labelle RJ, Willan A. In search of power and significance: issues in the design and analysis of stochastic cost-effectiveness studies in health care. Medical Care 1994;32(2):150-163.
25.Weinstein MC, Stason WB. Foundations of cost-effectiveness analysis for health and medical practices. N Engl J Med 1977;296(13):716-21.
26.Xuan J, Duong PT, Russo PA. The economic burden of congestive heart failure in a managed care population. Am J Manag Care 2000;(6):693-700.
27.Krumholz HM. Clinical correlates of in- hospital costs for acute myocardial infarction in patients 65 years of age. Am Heart J 1998;135:523-31.
28.American Heart Association Metropolitan Life Insurance Company Statistical Bulletin 1995.
29.Hlatky MA. Economics and cost- effectiveness in evaluating the value of cardiovascular therapies. Role of economic models in randomized trials. Am Heart J
30.Data from the Canadian Institute of Health Information (CIHI) for the period 31.April 1, 2000 to March 31, 2001, adapted by Drug Intelligence Inc.
32.Grover et al. The importance of indirect costs in primary cardiovascular disease prevention: can we save lives and money with statins? Archives of Internal Medicine. Forthcoming.